National Pharmaceuticals Corp. (PINK:NFRM) reached up 81.82% in morning trading to $.06 with 2M shares traded. National Pharmaceuticals Corp. is a Pharmaceutical Research and Development Corporation focused on leading edge technologies for treatment of human diseases. The company has embarked into the business of licensing mid stage development drugs for further development and marketing worldwide. National Pharmaceuticals Corp. (PINK SHEETS:NFRM - News) or the "Company" announced today that its partner, Globe Laboratories concluded that GLB333, the Company's Lead Therapeutic drug may have effect in the treatment of Lupus. Lupus complications are caused by over expression of certain cytokine (interleukins) according to several scientific reports. The drug GLB333 is an inhibitor of a cytokine that is involved in lupus. Globe Labs has indicated that the drug should be beneficial to treat lupus, due to its inhibitory action on cytokine or interleukin function.
Colorado Goldfields Inc. (PINK:CGFIA) reached up 57.14% in morning trading to $.0011 with 26M shares traded. Colorado Goldfields Inc. is a Denver-based junior exploration and mining company primarily exploring for gold and silver. Colorado Goldfields Inc. (Pinksheets:CGFIA - News) (Pinksheets:CGFIA - News) announces pre-payment, bringing the total financial warranty funded by the Company to $416,892, pursuant to the joint stipulation with the Division of Reclamation, Mining and Safety ("DRMS"). This pre-payment reflects the confidence of the Company's investors in the Pride of the West Mill project.
Orchid Cellmark Inc. (NASDAQ:ORCH) reached up 38.31% in morning trading to $2.78 with 5M shares traded. Orchid Cellmark is a leading international provider of DNA testing services primarily for forensic and family relationship applications. Orchid Cellmark is one of the largest providers of forensic DNA testing services and its DNA results are used by the criminal justice system to assist with the identification of perpetrators, the exclusion of suspects and the exoneration of wrongfully convicted individuals. Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH - News) and Orchid Cellmark Inc. (NASDAQ:ORCH – News) today announced that they have entered into a definitive agreement and plan of merger under which LabCorp will acquire all of the outstanding shares of Orchid Cellmark in a cash tender offer for $2.80 per share for a total purchase price to stockholders and optionholders of approximately $85.4 million. Orchid Cellmark strengthens LabCorp’s presence and strong brand name in identity testing in the US and establishes its presence in identity testing in the UK.
For a detailed quote on any of the following companies, or to read the full news articles visit PennyTrader.com
About PennyTrader.com
PennyTrader.com is a financial and investor relations website committed to covering the microcap market space including Pink Sheets and OTC Bulletin Board and sub-$5 big board stocks. We strive to provide you with the best stocks alerts in the market! We focus on OTCBB, OTC, penny stocks, sub-$5 big board stocks, and timely stocks picks and alerts. Our goal is to inform you of the HOTTEST stocks in the market before they move. Our staff has years experience in the stock market, and we are confident that you’ll be impressed with the results of our stock picks! If you wish to feature your organization on our website then you can contact us at publisher@pennytrader.com.
Disclosure: PennyTrader.com is not currently being compensated for any stocks covered in this midday report.
PennyTrader.com is not a registered investment advisers or broker/dealer. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this press release is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the micro cap companies covered and the potential lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. For our full disclaimer go to CLICK HERE
